Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PZ HTL SA

Bead-Based Assay Kits to Boost Metabolic and Hormone Research

By BiotechDaily International staff writers
Posted on 28 Jul 2014
Bio-Rad\'s Bio-Plex Pro RBM Magnetic Bead-Based Assay
The Bio-Plex Pro RBM Magnetic Bead-Based Assay (Photo courtesy of BIO-RAD LABORATORIES)
A new line of magnetic bead, microtiter plate-based metabolic assay kits is now available for use by biotech and other life science researchers.

The Bio-Rad Laboratories, Inc. (Hercules, CA, USA) Bio-Plex Pro RBM Human Metabolic and Hormone Assay line comprises kits for the analysis of seven panels of highly relevant biomarkers involved in diabetes, obesity, metabolic syndrome, cardiovascular disease (CVD), and hormonal control of metabolism and reproductive organs. The kits were developed in partnership with Myriad RBM, Inc., (Austin, TX, USA).

In the standard format, each kit contains one 96-well microtiter plate, magnetic capture beads, detection antibodies, standards, two-level controls, diluent, buffers, streptavidin-PE, and plate seals for the detection of up to eight human metabolic markers.

The assays are built on a magnetic bead platform, which allows data to be reported within three and a half hours. The kit format enables robust quantification of multiple proteins in human serum, plasma, and cell culture media samples. Kits are offered for research involving gut hormones and adipokines, pituitary hormones, diabetes (type I and type II), metabolic syndrome, obesity, CVD, and inflammation.

The Bio-Plex Pro RBM Human Metabolic and Hormone Assay line of kits is compatible with the Bio-Plex 100/200, Bio-Plex 3D, and Bio-Plex MAGPIX analytical platforms, as well as all other Luminex-based xMAP instruments and software.

Related Links:
Bio-Rad Laboratories, Inc.
Myriad RBM, Inc.




Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to BiotechDaily.com and get complete access to news and events that shape the world of biotechnology.
Free digital version edition of Bio Research International sent by email on regular basis
Free print version of Bio Research International magazine
(available only outside USA and Canada).
Free and unlimited access to back issues of Bio Research International in digital format
Free Bio Research International Newsletter sent every 2 weeks containing the latest news
Free breaking news sent via email
Free access to Events Calendar
Free access to LinkXpress new product services
REGISTRATION IS FREE AND EASY!


Click here to Register

Sign in: Registered website members
Username: Password:
Forgot username/password? Click here!
Sign in: Registered magazine subscribers
Subcode: Last Name:
What is SUBCODE?


comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Drug Discovery

view channel
Image: Disruption and removal of malaria parasites by the experimental drug (+)-SJ733 (Photo courtesy of the University of California, San Francisco).

Experimental Antimalaria Drug Induces the Immune System to Destroy Infected Red Blood Cells

An experimental drug for the treatment of malaria was found to induce morphological changes in infected erythrocytes that enabled the immune system to recognize and eliminate them. Investigators at... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.